The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase
Not applicable
Started
2025-06-20
Last updated
2026-01-20
Condition(s) studied
Alzheimer DiseaseBiomarker in Early Diagnosis
Investigational drug(s) / intervention(s)
Collect peripheral blood, and if the patient consents, also collect cerebrospinal fluid.
Collect peripheral blood, and if the patient consents, also collect cerebrospinal fluid.: Collect peripheral blood, and if the patient consents, also collect cerebrospinal fluid.
Study summary
Alzheimer's disease is the most common memory loss disease among the elderly. This disease affects the patient's memory, language, attention, and behavioral abilities. Current research has found that in the early stages of the disease, synaptic connections between brain nerve cells become abnormal, but the specific cause is still unclear. Investigators' previous research discovered that in the brains of diseased mice, certain special substances (the miR 342 5p/AnkG-mediated pathway) might be related to this abnormality, and these substances can be detected in both blood and cerebrospinal fluid. Therefore, investigators want to further explore the specific mechanisms of abnormal nerve cell connections, seek biomarkers for early detection of the disease, and provide new ideas for early diagnosis in the future.
Eligibility
Sex
ALL
Min age
50 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
Inclusion criteria for AD group:
1. Meet the diagnostic criteria for "probable AD dementia" established by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)
2. MMSE score between 0-23 points, Clinical Dementia Rating (CDR) score ≥0.5 points, Hachinski Ischemic Score \<4 points
3. Brain MRI showing bilateral temporal lobe and hippocampal atrophy
4. Age ≥50 years
Inclusion criteria for control group:
1. Healthy subjects with age matched to the AD group
2. Normal cognitive function and good activities of daily living
3. No dementia patients among first-degree relatives
4. Negative brain MRI and neurological examination
Exclusion Criteria:
1. Dementia or cognitive impairment caused by other diseases
2. History of substance abuse
3. Progressive primary aphasia
4. Previous traumatic brain injury
5. Patients with comorbid depression, schizophrenia, or severe diseases of the cardiovascular, hepatic, renal, or hematological systems
6. Impaired consciousness and inability to cooperate
7. Other conditions unsuitable for inclusion
Primary outcome measure(s)
Correlation between miR-342-5p/AnkG Pathway and Synaptic Proteins — Within 12 weeks after enrollment Quantitative Reverse Transcription-Polymerase Chain Reaction (QT-PCR) detection of microRNA-342-5p (miR-342-5p), Cytometric Bead Array (CBA) method detection of Ankyrin-G (AnkG), and Electrochemiluminescence (ECL) technology detection of neurogranin. Then analyze the correlation between miR-342-5p/AnkG and the synaptic protein neurogranin
Trial sites (1)
Facility
City
Region
Status
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Yiwu
Zhejiang
Recruiting
More The Fourth Affiliated Hospital of Zhejiang University School of Medicine trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.